Abstract
The evolution of crystal engineering into a form of supramolecular synthesis is discussed in the context of problems and opportunities in the pharmaceutical industry. Specifically, it has become clear that a wide array of multiple component pharmaceutical phases, so called pharmaceutical co-crystals, can be rationally designed using crystal engineering, and the strategy affords new intellectual property and enhanced properties for pharmaceutical substances.
| Original language | English |
|---|---|
| Pages (from-to) | 1889-1896 |
| Number of pages | 8 |
| Journal | Chemical Communications |
| Issue number | 17 |
| DOIs | |
| Publication status | Published - 7 Sep 2004 |
| Externally published | Yes |
Fingerprint
Dive into the research topics of 'Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver